Stage III Grade 3 Follicular Lymphoma Recruiting Phase 1 / 2 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0028630 (Stage III Grade 3 Follicular Lymphoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02213913Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasTreatment
NCT01805037Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTreatment